These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 15567093)

  • 1. Monoclonal antibody hNM01 in HIV-infected patients: a phase I study.
    Dezube BJ; Doweiko JP; Proper JA; Conway B; Hwang L; Terada M; Leece BA; Ohno T; Mastico RA
    J Clin Virol; 2004 Dec; 31 Suppl 1():S45-7. PubMed ID: 15567093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody.
    Johansson S; Goldenberg DM; Griffiths GL; Wahren B; Hinkula J
    AIDS; 2006 Oct; 20(15):1911-5. PubMed ID: 16988511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue.
    Murakami T; Eda Y; Nakasone T; Ami Y; Someya K; Yoshino N; Kaizu M; Izumi Y; Matsui H; Shinohara K; Yamamoto N; Honda M
    AIDS; 2009 Jul; 23(12):1485-94. PubMed ID: 19528788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
    Pett SL; McCarthy MC; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki JM; Williams KM; Emery S
    Antivir Ther; 2009; 14(1):111-5. PubMed ID: 19320244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of vaccination against hepatitis B in adult with HIV infection].
    Kalinowska-Nowak A; Bociaga-Jasik M; Garlicki A; Mach T
    Przegl Epidemiol; 2007; 61(2):339-47. PubMed ID: 17956052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
    Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
    Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells.
    Clayton R; Ohagen A; Goethals O; Smets A; Van Loock M; Michiels L; Kennedy-Johnston E; Cunningham M; Jiang H; Bola S; Gutshall L; Gunn G; Del Vecchio A; Sarisky R; Hallenberger S; Hertogs K
    J Virol Methods; 2007 Jan; 139(1):17-23. PubMed ID: 17034868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
    Herbeuval JP; Shearer GM
    AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
    Lalezari J; Yadavalli GK; Para M; Richmond G; Dejesus E; Brown SJ; Cai W; Chen C; Zhong J; Novello LA; Lederman MM; Subramanian GM
    J Infect Dis; 2008 Mar; 197(5):721-7. PubMed ID: 18266604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
    Levin MJ; Gershon AA; Weinberg A; Song LY; Fentin T; Nowak B;
    J Infect Dis; 2006 Jul; 194(2):247-55. PubMed ID: 16779732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
    Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
    AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.
    Amara S; Dezube BJ; Cooley TP; Pantanowitz L; Aboulafia DM
    Clin Infect Dis; 2006 Nov; 43(9):1198-205. PubMed ID: 17029142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody.
    Verity EE; Williams LA; Haddad DN; Choy V; O'Loughlin C; Chatfield C; Saksena NK; Cunningham A; Gelder F; McPhee DA
    AIDS; 2006 Feb; 20(4):505-15. PubMed ID: 16470114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1.
    Wolfe EJ; Cavacini LA; Samore MH; Posner MR; Kozial C; Spino C; Trapnell CB; Ketter N; Hammer S; Gambertoglio JG
    Clin Pharmacol Ther; 1996 Jun; 59(6):662-7. PubMed ID: 8681491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection.
    Robinson JE; Elliott DH; Martin EA; Micken K; Rosenberg ES
    Hum Antibodies; 2005; 14(3-4):115-21. PubMed ID: 16720981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
    Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.